Reported 6 months ago
A study by Stanford University researchers found that a 15-day course of Pfizer's COVID-19 antiviral treatment, Paxlovid, did not alleviate symptoms of long COVID. Despite hopes that the two-drug oral treatment would help long COVID patients, the study of 155 participants over 15 weeks showed no significant improvement in fatigue, brain fog, shortness of breath, body aches, or other symptoms. While the study indicated Paxlovid's safety over a 15-day period, it did not demonstrate efficacy in treating long COVID. Pfizer stated that these results will not affect their ongoing collaborative studies on Paxlovid as a potential treatment for long COVID, despite funding the trial.
Source: YAHOO